KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Patrick M. Reagan, John M. Timmerman et al.|New England Journal of Medicine|2020Cited by 1.9k
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 StudyMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Blood|2019Cited by 23
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 StudyMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Transplantation and Cellular Therapy|2020Cited by 6